P/E ratio for Xtant Medical (XTNT)
P/E ratio as of May 2024 (TTM): -8.00
According to Xtant Medical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.00111. At the end of 2022 the company had a P/E ratio of -6.60.
P/E ratio history for Xtant Medical from 2010 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -6.60 | -28.86% |
| 2021 | -9.28 | 277.79% |
| 2020 | -2.46 | -4% |
| 2019 | -2.56 | 788.1% |
| 2018 | -0.2881 | 43.8% |
| 2017 | -0.2003 | -46.3% |
| 2016 | -0.3731 | -91.52% |
| 2015 | -4.40 | 141.58% |
| 2014 | -1.82 | -17.21% |
| 2013 | -2.20 | -71.2% |
| 2012 | -7.64 | -80.57% |
| 2011 | -39.3 | 139.74% |
| 2010 | -16.4 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.